Head-To-Head Contrast: Kadmon (KDMN) versus Its Rivals
Kadmon (NYSE: KDMN) is one of 48 publicly-traded companies in the “Biopharmaceuticals” industry, but how does it contrast to its competitors? We will compare Kadmon to similar businesses based on the strength of its valuation, earnings, analyst recommendations, institutional ownership, dividends, risk and profitability.
This is a summary of recent ratings and price targets for Kadmon and its competitors, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Kadmon currently has a consensus target price of $9.75, indicating a potential upside of 173.11%. As a group, “Biopharmaceuticals” companies have a potential upside of 12.70%. Given Kadmon’s higher possible upside, analysts clearly believe Kadmon is more favorable than its competitors.
Institutional & Insider Ownership
51.9% of Kadmon shares are owned by institutional investors. Comparatively, 43.2% of shares of all “Biopharmaceuticals” companies are owned by institutional investors. 8.4% of Kadmon shares are owned by insiders. Comparatively, 15.5% of shares of all “Biopharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
This table compares Kadmon and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Risk and Volatility
Kadmon has a beta of 2.74, suggesting that its stock price is 174% more volatile than the S&P 500. Comparatively, Kadmon’s competitors have a beta of 1.09, suggesting that their average stock price is 9% more volatile than the S&P 500.
Valuation and Earnings
This table compares Kadmon and its competitors revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Kadmon||$26.06 million||-$208.75 million||-2.04|
|Kadmon Competitors||$564.12 million||$96.17 million||40.26|
Kadmon’s competitors have higher revenue and earnings than Kadmon. Kadmon is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Kadmon competitors beat Kadmon on 7 of the 12 factors compared.
Kadmon Company Profile
Kadmon Holdings, Inc. is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of various unmet medical needs. The Company is developing product candidates in a number of indications within autoimmune and fibrotic disease, oncology and genetic diseases. Its product pipeline consists of KD025, Tesevatinib and KD034. The Company’s other products include Ribasphere RibaPak, Ribasphere, Qsymia, Tetrabenazine and Valganciclovir. KD025 is an orally available, selective small molecule inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2), a molecular target in multiple autoimmune, fibrotic and neurodegenerative diseases. Tesevatinib is an oral tyrosine kinase inhibitor (TKI) designed to block key molecular drivers of tumor growth, metastases and drug resistance. KD034 is the Company’s portfolio of enhanced formulations of trientine hydrochloride for the treatment of Wilson’s disease.
Receive News & Ratings for Kadmon Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.